Indonesia’s Leading Eye-Care Giant JECX Targets $43 Million in Strategic IPO Expansion

[This article was updated at 18:30 p.m. on June 22, 2026 to clarify the use of the IPO proceeds]

JAKARTA, Investortrust.id — PT Nitrasanata Dharma Tbk, the powerhouse behind Indonesia’s premier eye-care network, Jakarta Eye Center (JEC), is officially hitting the public markets. The company confirmed its initial public offering (IPO) today, aiming to raise as much as Rp 683.17 billion ($43 million) to accelerate its national hospital footprint and solidify its leadership in the specialized medical sector.

The JECX listing represents a targeted play on one of Indonesia’s fastest-growing sub-sectors. Rising life expectancy, a growing middle class, and the high prevalence of diabetes-related vision complications have created a structural supply-demand gap for high-quality ophthalmology. By tapping into the public markets, JECX is aggressively moving to monopolize this niche, transforming from a specialized clinical chain into a dominant national medical powerhouse.

The offering includes 487.98 million shares, with half coming from existing shareholders via divestment and the remaining 50% consisting of new shares issued by the firm. The company has set an indicative price range between Rp 1,200 ($0.075) and Rp 1,400 ($0.088) per share, reflecting strong confidence in its growth trajectory.

Optimizing the Expansion Engine

Capital efficiency sits at the heart of the IPO strategy. Prior to the IPO, JECX used debt financing to accelerate expansion and construct new hospitals. After those assets became operational, the company is refinancing part of that expansion capital through an IPO, reducing leverage and freeing capacity for future growth.

JECX management stated that the proceeds from the initial public offering will be focused on strengthening the company’s financial structure and supporting business development. Approximately Rp 40 billion ($2.5 million) will be used to repay a portion of the company’s principal loan to PT Bank Central Asia Tbk (BBCA).

The debt being settled traces back to an aggressive expansion period in 2019–2024. The credit facilities being repaid were originally used to fund high-impact projects, including: acquiring land and renovating the JEC Tangerang clinic, purchase of advanced medical machinery, equipment for the Bekasi clinic, and various regional clinical upgrades, as well as funding equipment procurement for flagship facilities in Kedoya, Tambora, Pantai Indah Kapuk (PIK), Bandung, and Kendari.

Furthermore, the company has allocated approximately Rp 100 billion ($6.3 million) to settle a portion of its HSBC Indonesia loan facility, which remains fully undrawn since it was secured earlier this year.

The company also plans to provide additional capital to its subsidiary, PT Nitra Sanata Bali (NSB), amounting to approximately Rp 93.59 billion ($5.9 million), which will be utilized as working capital, including for land lease payments and operational requirements.

JECX will subsequently provide loans of Rp 100 billion ($6.3 million) to PT Orbita and Rp 35 billion ($2.2 million) to PT JEC Candi Sejahtera. These funds will be used by each respective subsidiary to repay a portion of their loan obligations to BCA.

The remaining funds will be utilized as the company’s working capital, including to support daily operational activities such as the payment of employee salaries and benefits through the end of 2027.

Capturing the Medical Tourism Opportunity

Beyond regional expansion, JECX is pivoting toward the high-value medical tourism market. The company is currently developing its JEC Bali@Sanur facility located within the Sanur Special Economic Zone. This project is specifically designed to attract high-net-worth international patients, cementing Indonesia’s position as a regional destination for specialized medical procedures.

Management projects that the Sanur facility will be operational by 2027, creating a dual-revenue stream that targets both local residents and international visitors. To maintain shareholder alignment, JECX has signaled a dividend policy of up to 50% of its net profit, subject to internal expansion requirements and standard annual general meeting approvals. PT Trimegah Sekuritas Indonesia Tbk is serving as the sole underwriter for this transaction.